A CAR-T therapy targeting b-cell maturation antigen (BCMA) in previously treated patients with multiple myeloma, has been granted breakthrough therapy designati 17 November 2017
Janssen Research and Development, a subsidiary of the US health care giant Johnson & Johnson, has presented Phase II data on Imbruvica (ibrutinib) in chronic gr 6 December 2016
Swiss pharma giant Novartis has responded to the growing competition to its off-patent product Gleevec (imatinib mesylate) by presenting the latest findings on 6 December 2016
Novartis (NOVN: VX) has described the findings of its trial of CTL019 in children and young adults with relapsed or refractory (r/r) B-cell acute lymphoblastic 6 December 2016
New data from the Phase III GALLIUM study has been presented at the 58th American Society of Hematology (ASH) annual meeting which suggests that Gazyvaro (obinu 5 December 2016
Data presented at the 58th American Society of Hematology (ASH) Annual Meeting has offered hope that the first new sickle cell-related pain crises (SCPC) option 5 December 2016
US biotech Celgene, the Dana-Farber Cancer Institute and the University of Arkansas for Medical Sciences have announced the creation of the Myeloma Genome Proje 5 December 2016
Denmark’s Novo Nordisk has announced new results on NovoSeven (rFVIIa), a portable room temperature stable recombinant activated factor VIIa, at the 58th Americ 5 December 2016
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.